About Zai Lab Limited
https://www.zailaboratory.comZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong.
CEO
Ying Du
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 29
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Citigroup
Buy
Leerink Partners
Outperform
Cantor Fitzgerald
Overweight
JP Morgan
Overweight
B of A Securities
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
CAPITAL WORLD INVESTORS
Shares:6.08M
Value:$119.18M
FMR LLC
Shares:4.7M
Value:$92.2M
CLEARBRIDGE INVESTMENTS, LLC
Shares:3.52M
Value:$69.01M
Summary
Showing Top 3 of 163
About Zai Lab Limited
https://www.zailaboratory.comZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $116.09M ▲ | $118.03M ▼ | $-35.96M ▲ | -30.98% ▲ | $-0.3 ▲ | $-30.66M ▲ |
| Q2-2025 | $109.98M ▲ | $121.65M ▼ | $-40.73M ▲ | -37.03% ▲ | $-0.37 ▲ | $-35.73M ▲ |
| Q1-2025 | $106.49M ▼ | $124.15M ▼ | $-48.44M ▲ | -45.49% ▲ | $-0.45 ▲ | $-43.79M ▲ |
| Q4-2024 | $109.07M ▲ | $134.87M ▲ | $-81.68M ▼ | -74.89% ▼ | $-0.8 ▲ | $-75.43M ▼ |
| Q3-2024 | $102.27M | $133.2M | $-41.67M | -40.75% | $-4.3 | $-38.05M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $717.15M ▼ | $1.16B ▼ | $399M ▲ | $759.95M ▼ |
| Q2-2025 | $732.16M ▼ | $1.16B ▼ | $372.37M ▲ | $791.74M ▼ |
| Q1-2025 | $757.26M ▼ | $1.17B ▼ | $362.58M ▲ | $810.75M ▼ |
| Q4-2024 | $779.67M ▲ | $1.19B ▲ | $344.86M ▲ | $840.9M ▲ |
| Q3-2024 | $616.09M | $985.35M | $317.68M | $667.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-35.96M ▲ | $-32.04M ▼ | $-4.05M ▼ | $20.79M ▲ | $-15.11M ▲ | $-36.13M ▼ |
| Q2-2025 | $-40.73M ▲ | $-31.02M ▲ | $-2.92M ▼ | $8.85M ▼ | $-24.99M ▼ | $-31.58M ▲ |
| Q1-2025 | $-48.44M ▲ | $-61.7M ▼ | $326.13M ▲ | $43.14M ▼ | $307.6M ▲ | $-65.57M ▲ |
| Q4-2024 | $-81.68M ▼ | $-55.77M ▼ | $-347.75M ▼ | $237.81M ▲ | $-166.42M ▼ | $-73.52M ▼ |
| Q3-2024 | $-41.67M | $-26.82M | $-29.89M | $42.21M | $-13.96M | $-56.71M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Nuzyra | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $10.00M ▼ |
 Optune | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Product and Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Qinlock | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Zejula | $140.00M ▲ | $40.00M ▼ | $50.00M ▲ | $40.00M ▼ |
CEO
Ying Du
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 29
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Citigroup
Buy
Leerink Partners
Outperform
Cantor Fitzgerald
Overweight
JP Morgan
Overweight
B of A Securities
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
CAPITAL WORLD INVESTORS
Shares:6.08M
Value:$119.18M
FMR LLC
Shares:4.7M
Value:$92.2M
CLEARBRIDGE INVESTMENTS, LLC
Shares:3.52M
Value:$69.01M
Summary
Showing Top 3 of 163